Poster Session 3
Category: Clinical Obstetrics
Poster Session 3
Nidhi Bhide (she/her/hers)
Medical Student
University of South Florida, Morsani College of Medicine
Saint Augustine, Florida, United States
Chinyere N. Reid, CPH, MBBS, MPH, PhD
University of South Florida College of Public Health
Tampa, Florida, United States
Meera Ratani, MD
Resident Physician
Department of Pediatrics, University of South Florida
Tampa, Florida, United States
Tanner G. Wright, MD
Associate Professor
Department of Pediatrics, The University of South Florida
Tampa, Florida, United States
Emily Coughlin
University of South Florida Morsani College of Medicine
Tampa, Florida, United States
Jennifer Marshall, CPH, MPH, PhD
University of South Florida College of Public Health
Tampa, Florida, United States
Anthony M. Kendle, MD (he/him/his)
Assistant Professor
Department of Obstetrics and Gynecology, University of South Florida
Tampa, Florida, United States
Opioid use disorder (OUD) during pregnancy is a leading cause of morbidity and mortality. The CADENCE (Continuous and Data-Driven Care) Program integrates perinatal, pediatric, behavioral health, and addiction medicine for patients with OUD. We hypothesized that utilization of the CADENCE program would result in higher rates of medication for OUD (MOUD) use at time of delivery.
We conducted a retrospective cohort study of pregnancies with OUD from 09/01/2023-01/31/2025 at a single tertiary care center. Electronic medical records were reviewed for demographic and clinical data. The primary exposure was participation in the CADENCE Program based on patient attendance at more than one of the coordinated clinics prior to date of delivery. The primary outcome was MOUD utilization at the time of delivery. Secondary outcomes included completion of prenatal and postpartum visits, hepatitis C screening, obstetric complications, and postpartum depression screening. Data were compared using chi-square/Fisher’s exact test for categorical variables and Mann-Whitney U test for nonparametric variables. A p< 0.05 was considered significant.
A total of 135 dyads met inclusion criteria. Sixty-six (48.9%) participated in the CADENCE Program. Patients in the CADENCE group were more likely to have MOUD enrollment at delivery compared to the non-CADENCE group (71.8% vs. 28.2%, p< 0.001). Of the 71 patients who had MOUD enrollment at delivery, 33 (46.5%) used methadone, 21(29.6%) used buprenorphine, and 17 (23.9%) used buprenorphine-naloxone. Distribution of MOUD was similar between groups. Patients in the CADENCE group were also significantly more likely to be screened for Hepatitis C (83% v 64%, p=0.010), attend a postpartum visit (64% v 45%, p=0.029), and have any prenatal care (86% v 67%, p=0.007). There was no statistically significant difference in obstetric complications at delivery or postpartum depression scores between groups.
Care coordination and evidence-based treatment through the CADENCE program increases gold-standard treatment with MOUD in pregnant individuals.